Researchers tested a new cannabis-derived treatment that significantly eased chronic lower back pain without causing dependency.
Patients reported marked improvements in pain intensity, mobility, and sleep after using the experimental drug VER-01 for several months.
Doctors see the therapy as a potential breakthrough for millions struggling with a condition that remains poorly treated worldwide.
Clinical Trial Results Highlight Pain and Function Gains
The large-scale study enrolled 820 adults who failed to respond adequately to non-opioid treatments.
Participants either received VER-01, developed by the German firm Vertanical, or a placebo for direct comparison.
They tracked pain intensity on a 0–10 scale, with higher scores reflecting unbearable pain levels.
After three months, VER-01 users reported a 1.9-point reduction, while placebo recipients showed only a 0.6-point drop.
In a six-month extension, VER-01 reduced scores by another 1.1 points and boosted physical performance.
Patients also slept more soundly and handled daily activities with greater ease, according to recorded outcomes.
The journal Nature Medicine published the findings, drawing attention from pain specialists worldwide.
Experts stressed that the relief level reached clinical significance, making the therapy valuable for real-world patients.
Distinct From Cannabis Smoking, With Fewer Risks
VER-01 comes from Cannabis sativa but differs entirely from recreational marijuana in composition and delivery.
Each measured dose carries 2.5 milligrams of THC alongside other active components carefully balanced for medical use.
Patients did not display addictive behaviors or misuse patterns, a concern with traditional painkillers like opioids.
Reported side effects included short-lived dizziness, nausea, and fatigue, all of which patients tolerated without serious harm.
Neuroscience lecturer Jan Vollert urged caution, reminding people that VER-01 cannot be compared to smoking cannabis.
He explained the distinction with an analogy, likening Nutella and hazelnuts: related in origin but fundamentally different.
Researchers now plan further studies comparing VER-01 directly with opioids to test its long-term effectiveness.
If confirmed, the therapy could reduce reliance on dangerous drugs and offer a safer pathway for chronic pain care.
